France's ANSM orders French biotech Theravectys to suspend manufacturing

Another French biotech has had its clinical supply manufacturing shut down by French drug regulator ANSM, after inspectors found a number of serious problems. According to a recent report posted by the European Medicines Agency, ANSM inspectors in November took a look at Theravectys in Villejuif, France, a biotech which is producing lentiviral vectors for clinical development and doing cell work for chimeric antigen receptors (CARs) and T-cell receptor (TCR)-based cell therapies. The facility was only approved in April of last year. During the inspection, they found 45 deficiencies, 5 of which they deemed critical and 17 major. They included testing media fill with "unqualified equipment." Last year, regulators recommended the same action against TxCell, a French biotech working on T-cell treatments for chronic inflammatory and autoimmune diseases. TxCell has since transferred its manufacturing to a contractor. Access the EMA report here | More

Suggested Articles

The antidepressant Zoloft and its generics are in short supply as the COVID-19 pandemic has caused higher demand and manufacturing interruptions.

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.